Tool - Prostate cancer screening

Les données de l’European Randomised Study of Screening for Prostate Cancer (ERSPC) ont été utilisées pour illustrer la balance entre les risques et les bénéfices potentiels

The objectives of this study are to quantify changes in PSA testing in Ontario males aged 35 or older from 2003 to 2012, and to study the associa- tion of selected factors,

Of the 57 men considered in the study, 54 (95%) believed that using the PSA blood test as a screening tool for prostate cancer was not risky, 39 (68%) believed that the PSA blood

L et’s  be  clear.  We  need  to  acknowledge  at  least  one  point:  the  introduction  of  systematic  screening  for  prostate  cancer  substantially 

The efficacy of treatment for prostate cancer is well docu- mented.  A  Swedish  study 3   demonstrated  that 

Somewhat less than one in ten women in this age group in the EU (8%) is targeted by regional cervical cancer screening programmes in five Member States, with a

• The number of new prostate cancer cases and deaths will almost double by 2030 in Latin America and the Caribbean if current trends continue.. Proportion of new cases

 ere is little doubt that PSA can detect prostate cancer. A study of 22 071 healthy men aged 40 to 82 years who had serum stored at baseline showed that 366 developed